Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In?

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments